Japan Approves Four Drugs Of Swiss-Based Novartis
This article was originally published in PharmAsia News
Executive Summary
Japan regulators have approved four drugs made by Switzerland-based Novartis, one each for asthma, blindness, cancer and hypertension. The approved drugs are Xolair (omalizumab) for severe bronchial asthma in adults, Tasigna (nilotinib) for Philadelphia chromosome-positive chronic myeloid leukemia, Lucentis (ranibizumab) for wet age-related macular degeneration and Diovan (valsartan; hydrochlorothiazide) for treating high blood pressure. Macular degeneration afflicts about 20,000 Japanese annually. (Click here for more